AdBio https://adbio.partners French Life Sciences Venture Capital Firm Wed, 04 Mar 2026 09:43:21 +0000 en-US hourly 1 https://adbio.partners/wp-content/uploads/2021/11/cropped-fav-32x32.png AdBio https://adbio.partners 32 32 AndzonBio2 Strengthens Scientific and Strategic Capabilities with New Advisory Board and Leadership Appointment https://adbio.partners/2026/03/04/andzonbio2-strengthens-scientific-and-strategic-capabilities-with-new-advisory-board-and-leadership-appointment/ Wed, 04 Mar 2026 09:42:34 +0000 https://adbio.partners/?p=2176 Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZITM, the First and Only Combination Eye Drop Approved to Treat Presbyopia https://adbio.partners/2026/01/29/tenpoint-therapeutics-ltd-announces-fda-approval-of-yuvezzitm-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia/ Thu, 29 Jan 2026 11:08:07 +0000 https://adbio.partners/?p=2161 Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI™ https://adbio.partners/2026/01/29/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi/ Thu, 29 Jan 2026 11:05:28 +0000 https://adbio.partners/?p=2160 Calida Therapeutics, startup lauréate du « Golden Ticket » ! https://adbio.partners/2026/01/29/calida-therapeutics-startup-laureate-du-golden-ticket/ Thu, 29 Jan 2026 09:47:49 +0000 https://adbio.partners/?p=2157 Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort https://adbio.partners/2026/01/09/agomab-announces-positive-phase-1-interim-results-with-agmb-447-in-healthy-participants-and-initiation-of-idiopathic-pulmonary-fibrosis-cohort/ Fri, 09 Jan 2026 10:04:33 +0000 https://adbio.partners/?p=2148 Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease https://adbio.partners/2025/11/24/agomab-announces-positive-topline-phase-2a-data-for-ontunisertib-in-fibrostenosing-crohns-disease/ Mon, 24 Nov 2025 09:57:56 +0000 https://adbio.partners/?p=2144 SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial https://adbio.partners/2025/10/30/sparingvision-doses-first-patient-with-spvn20-for-advanced-retinitis-pigmentosa-in-nyrvana-trial/ Thu, 30 Oct 2025 16:14:11 +0000 https://adbio.partners/?p=2101 AndzonBio2 emerges from stealth mode and announces initial €3M seed funding to advance breakthrough treatments for neurological disorders https://adbio.partners/2025/10/23/andzonbio2-emerges-from-stealth-mode-and-announces-initial-e3m-seed-funding-to-advance-breakthrough-treatments-for-neurological-disorders/ Thu, 23 Oct 2025 07:44:01 +0000 https://adbio.partners/?p=2096 SparingVision Highlights Advances in Gene-Agnostic Gene Therapies at ESGCT 2025 https://adbio.partners/2025/10/09/sparingvision-highlights-advances-in-gene-agnostic-gene-therapies-at-esgct-2025/ Thu, 09 Oct 2025 14:21:06 +0000 https://adbio.partners/?p=2089 ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 https://adbio.partners/2025/09/17/arthex-biotech-upsizes-series-b-financing-round-to-87m/ Wed, 17 Sep 2025 13:05:27 +0000 https://adbio.partners/?p=2065